Form D · Pharmaceuticals
LB PHARMACEUTICALS INC
New York, NY · CIK 0001691082
Offering snapshot reported Jan 10, 2024 · SEC filing
- Reported sold
- $111M Offering amount: $111M
- Investors reported
- 6 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Aug 29, 2023 As reported in this filing
Fundraising history
Reported soldDates are filing dates, not cash receipt dates. Decreases are reported revisions, not evidence of withdrawals. Separate offering histories are not added together.
What changed?
Latest filing versus its linked predecessor, where available.
- Reported sold$70,730,354 → $110,730,354
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jan 10, 2024 | Amendment | $110,730,354 | $40,000,000vs Sep 21, 2023 | 6 | SEC filing |
| Sep 21, 2023 | Initial | $70,730,354 | No comparison | 6 | SEC filing |
| Nov 23, 2022 | Amendment | $16,574,000 | $9,649,000vs Nov 1, 2022 | 71 | SEC filing |
| Nov 1, 2022 | Initial | $6,925,000 | No comparison | 21 | SEC filing |
| Jul 6, 2022 | Initial | $903,350 | No comparison | 35 | SEC filing |
| Sep 1, 2020 | Initial | $4,629,200 | No comparison | 35 | SEC filing |
| Dec 12, 2018 | Initial | $6,326,835 | No comparison | 74 | SEC filing |
| Aug 27, 2018 | Initial | $443,200 | No comparison | 7 | SEC filing |
| May 29, 2018 | Initial | $330,000 | No comparison | 11 | SEC filing |
| Apr 6, 2017 | Initial | $462,000 | No comparison | 8 | SEC filing |
| Dec 15, 2016 | Initial | $968,945 | No comparison | 13 | SEC filing |
Offering details
- Securities
- Equity, Option to acquire
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $2.47M
- Finders' fees
- $735K
- Form D file number
- 021-492682
The total offering amount of $110,730,354 consists of $75,000,000 new cash offering and $35,730,354 automatic conversion of existing convertible notes, for which notes (including underlying securities) a Form D was previously filed upon the original sale.
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| Maxim Group LLC | 120708 | |
| Agile Capital Markets | None | Agile Capital Markets |
Source: Form D, filed Jan 10, 2024. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Simon Basseyn | Director |
| Anna Eramo | Executive |
| Vincent Grattan | Director |
| Rajul Jain | Director |
| Rebecca Luse | Director |
| Ran Nussbaum | Director |
| Mark Panoff | Executive |
| Marc Panoff | Executive |
| Piero Poli | Director |
| Zachary Prensky | Director, Executive |
| Robert Ruffolo | Director |
| Lauren Stipp | Executive |
| Edmund Sullivan | Director |
| Andrew Vaino | Executive |
| Chen Yu | Director |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
575 Madison Avenue
New York, NY, 10022
New York, NY, 10022